HER2-positive advanced breast cancer treatment in 2020

被引：89

作者：

Cesca, Marcelle G. ^{[1
]}

Vian, Lucas ^{[1
]}

Cristovao-Ferreira, Sofia ^{[2
,3
,4
]}

Ponde, Noam ^{[1
]}

de Azambuja, Evandro ^{[2
,3
]}

机构：

[1] AC Camargo Canc Ctr, Clin Oncol Dept, Sao Paulo, Brazil

[2] Inst Jules Bordet, Brussels, Belgium

[3] Univ Libre Bruxelles ULB, Brussels, Belgium

[4] Inst Portugues Oncol Francisco Gentil, Lisbon, Portugal

来源：

CANCER TREATMENT REVIEWS | 2020年 / 88卷

关键词：

Advanced breast cancer; HER2-positive disease; Anti-HER2; treatments; Sequential treatment; Biomarkers; LAPATINIB PLUS CAPECITABINE; CIRCULATING TUMOR DNA; PHASE-II TRIAL; TRASTUZUMAB EMTANSINE; OPEN-LABEL; PHYSICIANS CHOICE; AMERICAN SOCIETY; BRAIN METASTASES; HER2; MUTATIONS; DOUBLE-BLIND;

D O I：

10.1016/j.ctrv.2020.102033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

HER2-positive breast cancer is an aggressive subtype identified in the 1980s. The development of therapies targeting the HER2 has improved outcomes. The current standard of care, established in 2012 is dual blockade with trastuzumab + pertuzumab as first-line followed by TDM-1 as second-line. Several suboptimal choices are available in third-line or more. In 2019 the presentation of several trials evaluating new drugs and regimens in third-line has re-opened questions about sequencing, treatment of triple positive disease and treatment choice after exposure to TDM-1. These include tucatinib, neratinib and trastuzumab-deruxtecan. Other agents - including other antibody drug conjugates and bispecific antibodies as well as combinations - will lead to further changes in coming years. Additionally, should the numerous putative biomarkers thus identified ever come into use at the clinic, choice of treatment and response evaluation may be substantially changed.

引用

页数：12

共 92 条

[1] SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer [J].

Aftimos, P. G. ;

van Herpen, C. M. ;

Mommers, E. C. ;

Koper, N. P. ;

Goedings, P. ;

Oesterholt, M. ;

Awada, A. ;

Desar, I. M. ;

Lim, J. ;

Dean, E. ;

Rolfo, C. ;

Macpherson, I. ;

Banerji, U. .

CANCER RESEARCH, 2017, 77

[2]

[Anonymous], 2019, J CLIN ONCOL S

[3]

[Anonymous], 2019, Annals of Oncology, DOI DOI 10.1093/ANNONC/MDZ242

[4]

Atkinson C., CHARACTERIZATION MON

[5]

Awada A., IMPACT NERATINIB DEV

[6] Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer The NEfERT-T Randomized Clinical Trial [J].

Awada, Ahmad ;

Colomer, Ramon ;

Inoue, Kenichi ;

Bondarenko, Igor ;

Badwe, Rajendra A. ;

Demetriou, Georgia ;

Lee, Soo-Chin ;

Mehta, Ajay O. ;

Kim, Sung-Bae ;

Bachelot, Thomas ;

Goswami, Chanchal ;

Deo, Suryanarayan ;

Bose, Ron ;

Wong, Alvin ;

Xu, Feng ;

Yao, Bin ;

Bryce, Richard ;

Carey, Lisa A. .

JAMA ONCOLOGY, 2016, 2 (12) :1557-1564

[7] Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [J].

Bachelot, T. ;

Ciruelos, E. ;

Schneeweiss, A. ;

Puglisi, F. ;

Peretz-Yablonski, T. ;

Bondarenko, I. ;

Paluch-Shimon, S. ;

Wardley, A. ;

Merot, J. -L. ;

du Toit, Y. ;

Easton, V. ;

Lindegger, N. ;

Miles, D. ;

Bouzid, Kamel ;

Campone, Mario ;

Coudert, Bruno ;

Nowecki, Zbigniew ;

Errihani, Hassan ;

Dalenc, Florence ;

Ferreira, Ana ;

Mano, Max ;

Ricci, Francesco ;

Kalofonos, Haralabos ;

Andreetta, Claudia ;

Montemurro, Filippo ;

Barrett, Sophie ;

Zhang, Qingyuan ;

Mavroudis, Dimitris ;

Matus, Juan ;

Beato, Carlos ;

Hu, Xichun ;

Gaafar, Rabab ;

Azeem, Hamdy Abdel ;

Perrin, Christophe ;

Ettl, Johannes ;

Lang, Istvan ;

Verma, Sunil ;

Li, Huiping ;

Brain, Etienne ;

Hoffmann, Oliver ;

Cariello, Anna ;

Tondini, Carlo ;

Altwegeiri, Taher ;

Loman, Niklas ;

Lux, Michael ;

Frassoldati, Antonio ;

Aziz, Zeba ;

Salas, Fernando ;

Streb, Joanna ;

Wronski, Andrzej .

ANNALS OF ONCOLOGY, 2019, 30 (05) :766-773

[8] Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study [J].

Bachelot, Thomas ;

Romieu, Gilles ;

Campone, Mario ;

Dieras, Veronique ;

Cropet, Claire ;

Dalenc, Florence ;

Jimenez, Marta ;

Le Rhun, Emilie ;

Pierga, Jean-Yves ;

Goncalves, Anthony ;

Leheurteur, Marianne ;

Domont, Julien ;

Gutierrez, Maya ;

Cure, Herve ;

Ferrero, Jean-Marc ;

Labbe-Devilliers, Catherine .

LANCET ONCOLOGY, 2013, 14 (01) :64-71

[9] Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go [J].

Barroso-Sousa, Romualdo ;

Tolaney, Sara M. .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (07)

[10] Activity of T-DM1 in HER2-positive breast cancer brain metastases [J].

Bartsch, Rupert ;

Berghoff, Anna S. ;

Vogl, Ursula ;

Rudas, Margaretha ;

Bergen, Elisabeth ;

Gnant, Michael ;

Dieckmann, Karin ;

Pinker, Katja ;

Bago-Horvath, Zsuzsanna ;

Galid, Arik ;

Oehler, Leopold ;

Zielinksi, Christoph C. ;

Steger, Guenther G. ;

Preusser, Matthias .

CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 6 7 8 9 10 →